59 -10 (84) 2025 - Jurayeva Y.O., Xalimova Z.Y. - CRANIOPHARYNGIOMAS: A MODERN VIEW OF THE PROBLEM

CRANIOPHARYNGIOMAS: A MODERN VIEW OF THE PROBLEM

Jurayeva Y.O. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Ya.Kh Turakulov,Ministry of Health of the Republic of Uzbekistan

Xalimova Z.Y. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Ya.Kh Turakulov,Ministry of Health of the Republic of Uzbekistan

Xolikova A.O. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Ya.Kh Turakulov,Ministry of Health of the Republic of Uzbekistan

Xakimov I.I. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Ya.Kh Turakulov,Ministry of Health of the Republic of Uzbekistan

Resume

Craniopharyngiomas are solid or solid-cystic tumors of dysembryogenetic origin, primarily localized in the sellar-parasellar region [18,20]. First described by Jakob Erdheim (1874–1937) as “pituitary duct tumors,” these neoplasms were classified into two types based on histological characteristics: an aggressive form, resembling jaw adamantinomas, and a more benign variant with papillary structures [11]. Recent molecular and genetic studies have confirmed these distinctions, and the WHO now classifies craniopharyngiomas into adamantinomatous (ACF) and papillary (PCF) subtypes [11,16]. Craniopharyngiomas account for 2–5% of all primary intracranial tumors. They are most prevalent in children aged 5–14 years (comprising 5–17% of intracranial neoplasms) and occur less frequently in adults aged 50–74 years [4,15]. This review explores current perspectives on the molecular and genetic characteristics, pathogenesis, diagnosis, and emerging therapeutic approaches for craniopharyngiomas.

Keywords: craniopharyngioma, brain tumors, neuropathology, immunotherapy, CTNNB1, BRAF-V600E.

First page

321

Last page

328

For citation:Jurayeva Y.O., Xalimova Z.Y., Xolikova A.O., Xakimov I.I. - CRANIOPHARYNGIOMAS: A MODERN VIEW OF THE PROBLEM//New Day in Medicine 10(84)2025 321-328 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

  1. Andoniadou CL, Matsushima D, Mousavy Gharavy SN, Signore M, Mackintosh AI, Schaeffer M, et al. Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. Cell Stem Cell. 2013 Oct;13(4):433–45.
  2. Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, et al. Tumour compartment transcriptomics demonstrate the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135(5):7.
  3. Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb;46(2):161–5.
  4. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998 Oct;89(4):547–51.
  5. Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrübl F, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol. 2005 Jun;109(6):589–97.
  6. Diaz MJ, Kwak SH, Root KT, Fadil A, Nguyen A, Ladehoff L, Batchu S, Lucke-Wold B. Current Approaches to Craniopharyngioma Management. Front Biosci (Landmark Ed). 2022 Dec 21;27(12):328. doi: 10.31083/j.fbl2712328. PMID: 36624954.
  7. Han Y, Wang Y, Li S, Sato K, Yamagishi S. Exploration of the shared pathways and common biomarker in adamantinomatous craniopharyngioma and type 2 diabetes using integrated bioinformatics analysis. PLoS ONE 19(6): e0304404. (2024) https://doi.org/10.1371/journal.pone.0304404
  8. Haston S, Pozzi S, Carreno G, Manshaei S, Panousopoulos L, Gonzalez-Meljem JM, et al. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development. 2017 Jun;144(12):2141–52.
  9. Li, S., Ye, Y., Nie, C. et al. Endoscopic endonasal transsphenoidal approach improves endocrine function and surgical outcome in primary craniopharyngioma resection: a systematic review and meta-analysis. World J Surg Onc 22, 137 (2024). https://doi.org/10.1186/s12957-024-03411-8
  10. Maikerly Reyes, Mohammad Taghvaei, Siyuan Yu, Anish Sathe, Sarah Collopy, Giyarpuram N. Prashant, James J. Evans, Michael Karsy. Targeted Therapy in the Management of Modern Craniopharyngiomas. Front Biosci (Landmark Ed) 2022, 27(4), 136. https://doi.org/10.31083/j.fbl2704136

    file

    download